logo
Plus   Neg
Share
Email

Varian To Buy Embolic Bead Asset From Boston Scientific - Quick Facts

Varian (VAR) said it will purchase a portfolio of drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products from Boston Scientific for a purchase price of $90 million. Varian will benefit from the regulatory clearances in more than 35 countries for the acquired assets.

"This acquisition will strengthen our growing position in the high-value interventional oncology segment and is consistent with our long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions," said Dow Wilson, CEO of Varian.

The deal is subject to approval of the U.S. FTC and the closing of the proposed acquisition of BTG plc by Boston Scientific Corp.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dunkin' Brands Group said it is rolling out the Beyond Sausage Sandwich to more than 9,000 restaurants nationwide, starting November 6. The sandwich features a plant-based sausage patty from alternative meat maker Beyond Meat. Beyond Meat's breakfast sausage patty is made with plant-based protein and a mix of spices crafted specifically for Dunkin'. Boeing said it understands and regrets the concern caused by the publications of instant messages involving a former test pilot that he "unknowingly" lied to regulators about a flight-control system on the Boeing 737 Max aircraft. The aircraft maker said it especially regrets the difficulties that the release of the messages presented for the U.S. Federal Aviation Administration or FAA. Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people.
RELATED NEWS
Follow RTT
>